Immune System News and Research

RSS

Scientists establish HCV infection in liver-like cells derived from iPSCs

Hepatitis C, an infectious disease that can cause inflammation and organ failure, has different effects on different people. But no one is sure why some people are very susceptible to the infection, while others are resistant. Scientists believe that if they could study liver cells from different people in the lab, they could determine how genetic differences produce these varying responses. However, liver cells are difficult to obtain and notoriously difficult to grow in a lab dish because they tend to lose their normal structure and function when removed from the body.

2 Feb 2012

ImmunoCellular receives U.S. patent allowance for cancer stem cell treatment

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of U.S. patent claims related to the Company's method of treating glioblastoma multiforme (GBM) in a patient by targeting cancer stem cells.

2 Feb 2012

Healthy lung tissue transplantation shows promise for patients with pulmonary diseases

For patients suffering from severe pulmonary diseases including emphysema, lung cancer or fibrosis, transplantation of healthy lung tissue may offer the best chance for survival. The surgical procedure, however, faces two primary challenges: an acute shortage of donor lungs and rejection of transplanted tissue by the recipient's immune system.

2 Feb 2012

Natural resistance to flu could hold key to universal vaccine

Researchers have found that on infecting 41 healthy volunteers with different strains of flu virus, those with higher levels of a specific type of white blood cell were less likely to develop severe illness. Now the team of researchers hopes to mimic the natural resistance shown by some of the volunteers, by creating a vaccine that boosts levels of a particular subset of the 'T-cells'.

1 Feb 2012

Peptides linked with internal flu viral structures can help develop universal vaccine

Researchers at the University of Southampton, University of Oxford and Retroscreeen Virology Ltd have discovered a series of peptides, found on the internal structures of influenza viruses that could lead to the development of a universal vaccine for influenza, one that gives people immunity against all strains of the disease, including seasonal, avian, and swine flu.

1 Feb 2012

Progenitor cells have potential to develop into RBCs

A study of the cells that respond to crises in the blood system has yielded a few surprises, redrawing the 'map' of how blood cells are made in the body.

1 Feb 2012

General anesthesia may lower recurrence risk in patients with HCC

For patients undergoing a minimally invasive treatment for liver cancer, the risk of recurrent cancer appears lower with general anesthesia compared to regional (epidural) anesthesia, reports a study in the February issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

1 Feb 2012

Majority of children can safely quit anti-rejection drugs after liver transplant from parents

Physicians at three transplant centers have found in a pilot study that a majority of children who receive liver tissue from a parent can eventually stop using immunosuppression (anti-rejection) medications safely. These drugs, which tamp down natural immune function, have been linked to a bevy of complications, including cancer, diabetes, hypertension and kidney failure.

1 Feb 2012

Preliminary results from CINJ's Celebrex and Lipitor Phase II combination trial on prostrate cancer

Research from The Cancer Institute of New Jersey (CINJ) on the FDA-approved drugs Celebrex and Lipitor -- used respectively for arthritis pain and lowering cholesterol -- shows that these drugs are well tolerated in the treatment of recurrent prostate cancer.

1 Feb 2012

Certain strains of P. aeruginosa cause WBCs to produce high levels of histamine

Could some cases of asthma actually be caused by an allergic reaction to a common environmental bacteria? New research findings published in the Journal of Leukocyte Biology suggests that this idea may not be as far-fetched as it seems. In a research report appearing in the February 2012 print issue, researchers show a link between common environmental bacteria and airway inflammation.

1 Feb 2012

NIAID, Aeras partner for Phase II clinical trial of TB vaccine

Aeras announces today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the United States National Institutes of Health (NIH), has joined as a partner for a Phase II proof-of-concept clinical trial of a tuberculosis vaccine candidate jointly developed by Aeras and Dutch biopharmaceutical company Crucell.

1 Feb 2012

Scientists identify TDO enzyme as new target for cancer therapy

Scientists from the Ludwig Institute for Cancer Research (LICR) in Brussels identified a new target for cancer therapy, an enzyme which prevents the immune system from recognizing and destroying certain types of tumors.

1 Feb 2012

New combination clinical trial may improve outcome for cancer surgery patients

The week before and two weeks after surgery are a critical period for the long-term survival rate of cancer patients. Physiological and psychological stresses caused by the surgery itself can inhibit the body's immune responses, heightening vulnerability to tumor progression and spreading.

1 Feb 2012

Pneumonic plague bacteria transform lungs into a playground for microbes to flourish

Among medical mysteries baffling many infectious disease experts is exactly how the deadly pneumonic plague bacterium, Yersinia pestis, goes undetected in the first few day of lung infection, often until it's too late for medical treatment.

1 Feb 2012

IMUC president to present at Immunotherapeutics Partnering and Deal Making Conference

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that its president and CEO, Manish Singh Ph.D., will be presenting at the Immunotherapeutics Partnering and Deal Making Conference, which will take place in San Diego, California on January 30-31, 2012.

31 Jan 2012

Study investigates trade-off between sperm quality and immunity

A new study shows the production of sperm is more biologically taxing than previously thought, and expending energy on it has significant health implications.

31 Jan 2012

Anti-HER2 dendritic cell vaccine shows promise against DCIS

Researchers at the Perelman School of Medicine at the University of Pennsylvania report that a short course of vaccination with an anti-HER2 dendritic cell vaccine made partly from the patient's own cells triggers a complete tumor eradication in nearly 20 percent of women with ductal carcinoma in situ (DCIS), an early breast cancer.

31 Jan 2012

Leprosy pathogen exploits micro-RNAs to weaken immune response

A team of UCLA scientists has found that the pathogen that causes leprosy has a remarkable ability to avoid the human immune system by inhibiting the antimicrobial responses important to our defenses.

30 Jan 2012

IGC researcher awarded ERC Advanced Grant for tissue damage study

There is more to fighting infection than just clearing the body of pathogens. As important as resisting infection, is limiting damage to the host's tissue caused, very frequently, by toxins produced by pathogens or by components of the host immune response that clears those pathogens.

30 Jan 2012

SENP1 prevents STAT5 from becoming trapped in nucleus

When SUMO grips STAT5, a protein that activates genes, it blocks the healthy embryonic development of immune B cells and T cells unless its nemesis breaks the hold, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports today in Molecular Cell.

30 Jan 2012